Amedeo Smart

Free Medical Literature Service



Ovarian Neoplasms

  Free Subscription

Articles published in
Ann Oncol
    June 2022
  1. FRENEL JS, Kim JW, Aryal N, Asher R, et al
    Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
    Ann Oncol. 2022 Jun 27. pii: S0923-7534(22)01740.
    >> Share

    April 2022
    For Ovarian Cancer PARPi maintenance therapy: more is better, right?
    Ann Oncol. 2022 Apr 7. pii: S0923-7534(22)00681.
    >> Share

    February 2022
  3. FRANCIS KE, Kim SI, Friedlander M, Gebski V, et al
    The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
    Ann Oncol. 2022 Feb 24. pii: S0923-7534(22)00338.
    >> Share

    January 2022
  4. DALMARTELLO M, La Vecchia C, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
    Ann Oncol. 2022 Jan 13. pii: S0923-7534(21)04881.
    >> Share

  5. MOORE KN, du Bois A
    Homologous recombination deficiency testing in first-line ovarian cancer.
    Ann Oncol. 2022 Jan 8. pii: S0923-7534(22)00004.
    >> Share

    November 2021
  6. VERGOTE I, Gonzalez-Martin A, Ray-Coquard I, Harter P, et al
    European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04828.
    >> Share

    August 2021
  7. MARTIN JE, Khalife-Hachem S, Grinda T, Kfoury M, et al
    Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.
    Ann Oncol. 2021;32:1046-1048.
    >> Share

    July 2021
  8. COLOMBO N, Ledermann JA
    Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines.
    Ann Oncol. 2021 Jul 14. pii: S0923-7534(21)02182.
    >> Share

  9. DI VINCENZO A, Andrisani A, Vettor R, Rossato M, et al
    Estrogen and COVID-19: friend or foe?
    Ann Oncol. 2021;32:933-934.
    >> Share

    June 2021
  10. MIRZA MR, Coleman RL, Gonzalez-Martin A, Moore KN, et al
    Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].
    Ann Oncol. 2021 Jun 2. pii: S0923-7534(21)02020.
    >> Share

    March 2021
  11. BAERT T, Ferrero A, Sehouli J, O Donnell DM, et al
    The Systemic Treatment of Recurrent Ovarian Cancer revisited.
    Ann Oncol. 2021 Mar 3. pii: S0923-7534(21)00155.
    >> Share

  12. MOORE KN, Oza AM, Colombo N, Oaknin A, et al
    Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
    Ann Oncol. 2021 Mar 2. pii: S0923-7534(21)00157.
    >> Share

    January 2021
  13. MONTOPOLI M, Zorzi M, Cocetta V, Prayer-Galetti T, et al
    Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy.
    Ann Oncol. 2021 Jan 29. pii: S0923-7534(21)00097.
    >> Share

  14. WU XH, Zhu JQ, Yin RT, Yang JX, et al
    Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase 3 trial.
    Ann Oncol. 2021 Jan 13. pii: S0923-7534(21)00008.
    >> Share

  15. TOBALINA L, Armenia J, Irving E, O'Connor MJ, et al
    A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
    Ann Oncol. 2021;32:103-112.
    >> Share

    December 2020
  16. PILIE PG, George A, Yap TA
    Patient selection biomarker strategies for PARP inhibitor therapy.
    Ann Oncol. 2020;31:1603-1605.
    >> Share

    September 2020
  17. MILLER RE, Leary A, Scott CL, Serra V, et al
    ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    Ann Oncol. 2020 Sep 28. pii: S0923-7534(20)42164.
    >> Share

    June 2020
  18. MIRZA MR, Coleman RL, Gonzalez-Martin A, Moore KN, et al
    The forefront of ovarian cancer therapy: update on PARP inhibitors.
    Ann Oncol. 2020 Jun 19. pii: S0923-7534(20)39891.
    >> Share

    May 2020
  19. MILLSTEIN J, Budden T, Goode EL, Anglesio MS, et al
    Prognostic gene expression signature for high-grade serous ovarian cancer.
    Ann Oncol. 2020 May 27. pii: S0923-7534(20)39841.
    >> Share

    February 2020
  20. WAKS AG, Cohen O, Kochupurakkal B, Kim D, et al
    Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055.
    >> Share

    July 2019
  21. MATULONIS UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
    Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
    Ann Oncol. 2019;30:1080-1087.
    >> Share

  22. GAILLARD SL, Coleman RL
    Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
    Ann Oncol. 2019;30:1025-1028.
    >> Share

    May 2019
  23. JOLY F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, et al
    Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.
    Ann Oncol. 2019;30:845-852.
    >> Share

  24. BUECHEL M, Herzog TJ, Westin SN, Coleman RL, et al
    Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.
    Ann Oncol. 2019;30:721-732.
    >> Share

  25. COLOMBO N, Sessa C, du Bois A, Ledermann J, et al
    ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
    Ann Oncol. 2019;30:672-705.
    >> Share

    April 2019
  26. LORUSSO D, Pignata S, Gonzalez-Martin A
    Chemotherapy-free treatments: are we ready for prime time?
    Ann Oncol. 2019;30:497-498.
    >> Share

  27. LIU JF, Barry WT, Birrer M, Lee JM, et al
    Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Ann Oncol. 2019;30:551-557.
    >> Share

    February 2019
  28. HUANG T, Tworoger SS, Willett WC, Stampfer MJ, et al
    Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.
    Ann Oncol. 2019;30:303-309.
    >> Share

  29. TRIFANESCU OG, Topliceanu F, Gusoiu BA, Gales LN, et al
    Reactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients.
    Ann Oncol. 2019;30 Suppl 1:i8-i9.
    >> Share

  30. STONE A, Gebski V, Davidson R, Bloomfield R, et al
    Exaggeration of PFS by blinded, independent, central review (BICR).
    Ann Oncol. 2019;30:332-338.
    >> Share

    July 2018
  31. BASU B, Krebs MG, Sundar R, Wilson RH, et al
    Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.
    Ann Oncol. 2018 Jul 17. pii: 5055047. doi: 10.1093.
    >> Share

    February 2018
  32. BIRKBAK NJ, Li Y, Pathania S, Greene-Colozzi A, et al
    Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple negative breast and serous ovarian cancers.
    Ann Oncol. 2018 Feb 14. pii: 4857262. doi: 10.1093.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016